T cell therapy called AIC100, which targets the ICAM-1 protein, demonstrated encouraging responses and an acceptable safety ...

Qianhangjiang Pharmaceutical Co. Ltd. has divulged somatostatin peptide analogues acting as somatostatin receptor type 2 (SSTR2) ligands reported to be useful for the treatment of cancer and ...

demonstrating remarkable efficacy against somatostatin receptor-2-positive neuroendocrine tumors (NETs), including small cell lung cancer (SCLC). Details of the study have been published in the ...

The following is a summary of "A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors ...

and constitutional symptoms (for example, fatigue) were moderately improved, as was the patients' quality of life. ...somatostatin receptor-targeting radiopharmaceuticals should be a last resort ...

Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced ...

However, the researchers hypothesized that the cone snail’s version of somatostatin, Consomatin G1, might also selectively target the hormone-regulating receptor SSTR 2 due to its structural ...

Because pituitary corticotroph adenomas express somatostatin receptors, somatostatin analogues have been investigated as a potential targeted therapy for the treatment of Cushing's disease.

Perspective Therapeutics, Inc.’s CATX share price has dipped by 5.02%, which has investors questioning if this is right time ...

Lead asset Paltusotine is an oral, selective, non-peptide, somatostatin receptor type 2 (SST2) agonist. An alternative to injectable broad spectrum somatostatin analogs, paltusotine is a non ...

The company’s products include SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2; developing SAR ...